Hemophilia Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026
Hemophilia is a hereditary genetic disorder where the body’s coagulation control or blood clotting ability is impaired. Basically, due to lack of sufficient amount of blood-clotting proteins or clotting factors, your blood is unable to clot normally. The inherited hemophilia is generally found in men as it is passed to them by the X chromosome of their mother. Hemophilia occurs in three forms – hemophilia A, hemophilia B and hemophilia C. The most commonly formed is the hemophilia A which is due to lack of factor VIII. Hemophilia B occurs due to lack of factor IX and hemophilia C occurs due to lack of factor XI. Utilization of innovative techniques and technological advancements are the driving force for the growth of the global market. According to World Federation of Hemophilia (WFH), hemophilia A affects 1 in 5000 males that take birth. It is estimated that around 75% of the global hemophilia patient pool has no proper access to treatment. Therefore, in order to provide consistent treatment for patients, agencies like Hemophilia Association of America (HAA) have pursued key market players for the introduction of co-pay assistance initiatives. For instance, CSL Behring made a donation of 1.5 million units of their anti-hemophilic agents on world hemophilia day which is on April 17. At present, there is no cure present for hemophilia A and treatments are primarily conducted to manage the disease. Due to the lack of provision of medical needs and monopolistic opportunities for manufacturers, there is a huge demand for effective hemophilia management. Also, due to the presence of limited amount of therapies and regulatory authorities facing a huge task on the treatment of these disorders, the research and development also get a boost so that they can identify curative agents which in turn will help to accelerate growth during the forecast period.
Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=196&page=requestsample
Insights on Hemophilia Treatment Market:
• North America
• Asia Pacific
• Latin America
• Rest of the world
North America is expected to be a major shareholder of the global market due to high awareness and supportive regulatory policies. European region follows North America and is expected to have a significant share during the forecast period. Asia Pacific regions are expected to experience a rapid market growth rate due to changing healthcare policies and increasing awareness. Latin America and the rest of the world are both expected to possess a small fraction of the global market due to lack of awareness.
By Type of Product
• Recombinant clotting factors concentrate
• Plasma derived factor concentrates
By Type of Disease
• Hemophilia A
• Hemophilia B
• Hemophilia C
Hemophilia A treatments are expected to grow at a higher rate in the market as compared to hemophilia B and hemophilia C during the forecast period due to the prevalence of the disease throughout the world.
By End User
The hospital segment is expected to get a boost in the market growth during the forecast period as more and more multi-speciality hospitals are being built which provide hemophilia treatments and has an infrastructural advantage over the clinics and this trend will be observed in the North American and European regions due to the high spending capacity of the general population. On the other hand, clinic treatments will obtain a rapid growth rate in emerging economies due to lesser treatment cost as compared to hospitals.
Purchase a Copy of this Premium Research Report At:
• Baxter International Inc.
• Bayer AG
• Biogen Idec Inc.
Baxter International Inc. has obtained approval for Obizur, which is a recombinant concentrate for treating hemophilia A which will help them get some market share during the forecast period because it is the first recombinant porcine FVIII treatment for acquired hemophilia A. Bayer has got their injection named Jivi FDA-approved last year for treatment for patients aged 12 or above which will help replace reduced or missing factor VIII and this too will help them acquire a good growth rate during the forecast period. Pfizer has initiated a phase-3 study for safety evaluation of current therapy of factor IX prophylaxis replacement therapy which will help them gain some traction in the market during the forecast period.
FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global hemophilia treatment market by region, by type of product, by type of disease, by end user, by market players
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Inquire further details about this report at: email@example.com
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Phone: +44 141 628 9353 / +1 970 279 4295
Country: United Kingdom
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026 here
News-ID: 1779694 • Views: 633
More Releases from FutureWise Research
Unit Drug Dose Delivery System Market Global Trends, Market Share, Industry Size …
Global Unit Drug Dose Delivery System Market is poised to register a CAGR of over 5% during the forecast period of 2019 to 2026. Patients have to receive accurate dosing of drugs which will improve the recovery rate of the patient hence unit drug delivery system is implemented by hospitals and clinics. This system is also efficient in maintaining drug storage and its disposal. These are some of the primary factors that
Vascular Sealing Systems Market Global Trends, Market Share, Industry Size, Grow …
Global vascular sealing systems market predicted to value over USD 1 billion by 2026 end and register a CAGR over 6% during the forecast period 2019 to 2026. The number of patients experiencing cardiovascular disease (CVD) are on a rise due to lack of physical activity, high blood pressure, changing lifestyle, addictions like alcohol consumption and smoking. According to the American Heart Association, CVD is the leading cause for mortality worldwide,
Implantable Pulse Generator Market Global Trends, Market Share, Industry Size, G …
A rise in various complex diseases and medical conditions has led the healthcare sector to push research and development boundaries which have resulted in a new age of disease treatment and one such technology is Implantable Pulse Generator (IPG). It is a micro-electronic medical device which is battery-powered that is inserted in the body where the nervous system is delivered with an electric stimulation which helps in stimulation or blocking
Hospital Acquired Pneumonia Treatment Market Global Trends, Market Share, Indust …
The global hospital acquired pneumonia treatment market is estimated to value over US$ 1.5 billion with a CAGR of 3% during the forecast period, 2019 to 2026 In the recent past, the public healthcare system is facing a difficult challenge in the form of Hospital Acquired Pneumonia (HAP). It is a type of pneumonia when a person is hospitalized for more than 48 hours. In pneumonia, the lungs are conditioned to an inflammatory
More Releases for Hemophilia
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes
Hemophilia Treatment Drugs Market Report 2024
Global Hemophilia Treatment Drugs Market: Overview The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia